KMT2A and acute myeloid leukemia: The combination of different biological factors to define AML prognosis has been evaluated by Santamaría et al. who recently conducted a multivariate analysis on 9 molecular markers (ERG, EVI1, MLL-PTD, MN1, PRAME, RHAMM, WT-1, NPM, and FLT3) in 121 patients with cytogenetically normal AML (CN-AML) [6].